SNOA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sonoma Pharmaceuticals Inc (SNOA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown revenue growth and improved financial metrics, the lack of significant trading signals, bearish moving averages, and no clear positive catalysts suggest that waiting for a better entry point or further developments would be prudent.
The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is neutral at 60.878, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 1.134, with resistance at 1.222 and support at 1.046.
Revenue for fiscal year 2026 increased by 48.3% year-over-year, and the net loss improved by 8%. EBITDA loss decreased by 38%, showing operational improvements.
The company is still operating at a net loss, and there are no significant insider or hedge fund trading trends. Additionally, no recent congress trading data or influential figure activity has been reported.
Sonoma Pharmaceuticals reported Q4 GAAP EPS of -$0.33 and revenue of $5.56 million, a 48.3% year-over-year increase. Fiscal year 2026 revenue was $19.5 million, up $5.2 million from fiscal year 2025. Net loss improved by $0.3 million to $3.2 million, and EBITDA loss decreased by $1.2 million to $2.1 million.
No analyst rating or price target changes were provided in the data.
